CG Oncology, Inc. (CGON)

CG Oncology's stock has increased by 200.31% between April 2, 2025, and April 1, 2026. Key events include a USD 380 million IPO in January 2024, a follow-on equity offering in Q4 2024, presentation of positive Phase 3 BOND-003 clinical trial data in December 2025, an expedited timeline for the PIVOT-006 Phase 3 topline data readout announced in January 2026, reporting 2025 year-end financial results and business updates in February 2026, and presentation of updated BOND-003 clinical results in May 2025.

There is no information to suggest any seasonality in the demand for CG Oncology, Inc.'s products or services. Demand for its product candidate is primarily driven by medical need, clinical efficacy, regulatory approvals, and market adoption, rather than seasonal fluctuations.

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing bladder-sparing therapeutics for bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Their primary product candidate is cretostimogene grenadenorepvec, an investigational engineered oncolytic immunotherapy (OIT) being evaluated in Phase 3 trials for high-risk BCG-unresponsive NMIBC with carcinoma in situ, as well as intermediate-risk NMIBC following TURBT. Additionally, it is being evaluated in Phase 2 trials in combination with pembrolizumab for high-risk BCG-unresponsive NMIBC and as monotherapy or in combination with gemcitabine for high-risk BCG-exposed and BCG-naïve NMIBC patients.

CG Oncology, Inc. is headquartered in Irvine, California, United States, with a significant presence of investors from the United States.

CG Oncology's brand reputation over the past year appears to be positive, driven by promising clinical trial results and active engagement in the scientific community. The company has presented data at major conferences and has a consensus rating of "Buy" from analysts, including a significant percentage recommending "Strong Buy."

CG Oncology, Inc. has a diverse ownership structure, with institutional investors holding a significant portion of the company's stock, approximately 63.08% to 76.99%. Major institutional owners include Vanguard Group Inc, Decheng Capital LLC, Wellington Management Group Llp, and BlackRock, Inc. Individual investors and public companies also hold stakes, with insiders owning about 10.37% of the stock, and Hong Fang Song owning the most shares among individual investors.